Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Medical
EPIC: POSC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Positron Corporation
www.positron.com

Positron Corporation offers innovative solutions through the production and distribution of molecular
imaging systems and radiopharmaceutical technologies.

Full Positron Corporation profile here
Pdf

Positron gets regulatory approval for $38 million disaster bond volume application

21st Sep 2011, 4:01 pm by Brad Lemaire
Positron gets regulatory approval for $38 million disaster bond volume application

Positron Corp (OTC:POSC), a molecular imaging company specializing in nuclear cardiology, reported on Wednesday that the Indiana Finance Authority (IFA) approved its $38 million disaster area bond volume cap application.
  
The CEO of the Indiana Economic Development Corp, Mitchell Roob, recommended to public finance director, Kendra York, for the IFA to award the Midwestern disaster bonds to Positron for its 70 mega electron volt cyclotron facility in Noblesville, Indiana.

Positron said that the bonds will be part of an overall long-term strategic investment the company is making in its proposed high energy 70 mega electron volt cyclotron project and radiopharmaceutical manufacturing facility in Noblesville, Indiana.

The facility, once completed, will be the highest energy commercial cyclotron, used to accelerate charged particles, for isotope production within the United States, and is expected to advance Positron’s goals for the production of medical isotopes and radiopharmaceuticals used in cardiac PET imaging, diagnostic and therapeutic applications.

On June 10, Positron announced it proposed to make a capital investment of about $55 million for the project in combination with significant economic development incentives from the city of Noblesville coupled with other project financing opportunities.

Positron provides molecular technologies and services that are reshaping the field of nuclear cardiology through its proprietary positron emission tomography imaging and radiopharmaceutical solutions with a strong commitment to advancing the practice and technology of nuclear medicine.

The Houston, Texas-based company’s stock nudged up 10.50% to 20 cents Wednesday late afternoon on the OTC markets.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.